Comment on

• Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density.

  Riggs BL, Melton LJ 3rd. Riggs BL, et al. J Bone Miner Res. 2002 Jan;17(1):11-4. doi: 10.1359/jbmr.2002.17.1.11. J Bone Miner Res. 2002. PMID: 11771656 No abstract available.
• Why is the age-standardized incidence of low-trauma fractures rising in many elderly populations?

  Kannus P, Niemi S, Parkkari J, Palvanen M, Heinonen A, Sievänen H, Järvinen T, Khan K, Järvinen M. Kannus P, et al. J Bone Miner Res. 2002 Aug;17(8):1363-7. doi: 10.1359/jbmr.2002.17.8.1363. J Bone Miner Res. 2002. PMID: 12162489
• Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.

  Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM; Fracture Intervention Trial Long-Term Extension Research Group. Ensrud KE, et al. J Bone Miner Res. 2004 Aug;19(8):1259-69. doi: 10.1359/JBMR.040326. Epub 2004 Mar 29. J Bone Miner Res. 2004. PMID: 15231012 Clinical Trial.
• Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong?

  Jaglal SB, Weller I, Mamdani M, Hawker G, Kreder H, Jaakkimainen L, Adachi JD. Jaglal SB, et al. J Bone Miner Res. 2005 Jun;20(6):898-905. doi: 10.1359/JBMR.041231. Epub 2004 Dec 20. J Bone Miner Res. 2005. PMID: 15883628